Aspirin response and failure in cerebral infarction

Cathy M. Helgason, Kathryn L. Tortorice, Susan R. Winkler, Donald W. Penney, James J. Schuler, T. J. McClelland, Larry D. Brace

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

Background and Purpose: The purpose of this study was to assess the biological effect of aspirin as measured by the inhibition of platelet aggregation in patients taking aspirin for stroke prevention and in patients with acute stroke. Methods: We administered increasing doses of aspirin (325, 650, 975, and 1,300 mg daily) to 113 patients for stroke prevention and measured the inhibition of platelet aggregation in these patients and in 33 patients with acute stroke taking aspirin before stroke onset. Results: Eighty-five patients on ≤325 and six on ≥650 mg aspirin daily had complete inhibition of platelet aggregation. Increase of the dose by 325 mg in nine of the 22 patients with partial inhibition of platelet aggregation produced complete inhibition in five patients at 650 mg and in one at 975 mg. At 1,300 mg, three patients still had only partial inhibition of platelet aggregation (aspirin resistance). Of the 33 inpatients with acute stroke, 24 had platelet aggregation studies done before further administration of aspirin. Of these, 19 had complete inhibition of platelet aggregation and three had partial inhibition, with production of complete inhibition of platelet aggregation at dose escalation; one patient was aspirin-resistant and the other noncompliant. Conclusions: How the inhibition of platelet aggregation relates to stroke prevention remains unclear. The ability of aspirin and the dose required to inhibit platelet aggregation may depend upon the individual.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalStroke
Volume24
Issue number3
DOIs
StatePublished - Mar 1993

Fingerprint

Cerebral Infarction
Platelet Aggregation
Aspirin
Stroke
Inpatients

Keywords

  • Aspirin
  • Cerebral infarction
  • Stroke prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Helgason, C. M., Tortorice, K. L., Winkler, S. R., Penney, D. W., Schuler, J. J., McClelland, T. J., & Brace, L. D. (1993). Aspirin response and failure in cerebral infarction. Stroke, 24(3), 345-350. https://doi.org/10.1161/01.STR.24.3.345

Aspirin response and failure in cerebral infarction. / Helgason, Cathy M.; Tortorice, Kathryn L.; Winkler, Susan R.; Penney, Donald W.; Schuler, James J.; McClelland, T. J.; Brace, Larry D.

In: Stroke, Vol. 24, No. 3, 03.1993, p. 345-350.

Research output: Contribution to journalArticle

Helgason, CM, Tortorice, KL, Winkler, SR, Penney, DW, Schuler, JJ, McClelland, TJ & Brace, LD 1993, 'Aspirin response and failure in cerebral infarction', Stroke, vol. 24, no. 3, pp. 345-350. https://doi.org/10.1161/01.STR.24.3.345
Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ et al. Aspirin response and failure in cerebral infarction. Stroke. 1993 Mar;24(3):345-350. https://doi.org/10.1161/01.STR.24.3.345
Helgason, Cathy M. ; Tortorice, Kathryn L. ; Winkler, Susan R. ; Penney, Donald W. ; Schuler, James J. ; McClelland, T. J. ; Brace, Larry D. / Aspirin response and failure in cerebral infarction. In: Stroke. 1993 ; Vol. 24, No. 3. pp. 345-350.
@article{ed29f44c6a9f4d5d9bd56c6de7ddefa2,
title = "Aspirin response and failure in cerebral infarction",
abstract = "Background and Purpose: The purpose of this study was to assess the biological effect of aspirin as measured by the inhibition of platelet aggregation in patients taking aspirin for stroke prevention and in patients with acute stroke. Methods: We administered increasing doses of aspirin (325, 650, 975, and 1,300 mg daily) to 113 patients for stroke prevention and measured the inhibition of platelet aggregation in these patients and in 33 patients with acute stroke taking aspirin before stroke onset. Results: Eighty-five patients on ≤325 and six on ≥650 mg aspirin daily had complete inhibition of platelet aggregation. Increase of the dose by 325 mg in nine of the 22 patients with partial inhibition of platelet aggregation produced complete inhibition in five patients at 650 mg and in one at 975 mg. At 1,300 mg, three patients still had only partial inhibition of platelet aggregation (aspirin resistance). Of the 33 inpatients with acute stroke, 24 had platelet aggregation studies done before further administration of aspirin. Of these, 19 had complete inhibition of platelet aggregation and three had partial inhibition, with production of complete inhibition of platelet aggregation at dose escalation; one patient was aspirin-resistant and the other noncompliant. Conclusions: How the inhibition of platelet aggregation relates to stroke prevention remains unclear. The ability of aspirin and the dose required to inhibit platelet aggregation may depend upon the individual.",
keywords = "Aspirin, Cerebral infarction, Stroke prevention",
author = "Helgason, {Cathy M.} and Tortorice, {Kathryn L.} and Winkler, {Susan R.} and Penney, {Donald W.} and Schuler, {James J.} and McClelland, {T. J.} and Brace, {Larry D.}",
year = "1993",
month = "3",
doi = "10.1161/01.STR.24.3.345",
language = "English (US)",
volume = "24",
pages = "345--350",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Aspirin response and failure in cerebral infarction

AU - Helgason, Cathy M.

AU - Tortorice, Kathryn L.

AU - Winkler, Susan R.

AU - Penney, Donald W.

AU - Schuler, James J.

AU - McClelland, T. J.

AU - Brace, Larry D.

PY - 1993/3

Y1 - 1993/3

N2 - Background and Purpose: The purpose of this study was to assess the biological effect of aspirin as measured by the inhibition of platelet aggregation in patients taking aspirin for stroke prevention and in patients with acute stroke. Methods: We administered increasing doses of aspirin (325, 650, 975, and 1,300 mg daily) to 113 patients for stroke prevention and measured the inhibition of platelet aggregation in these patients and in 33 patients with acute stroke taking aspirin before stroke onset. Results: Eighty-five patients on ≤325 and six on ≥650 mg aspirin daily had complete inhibition of platelet aggregation. Increase of the dose by 325 mg in nine of the 22 patients with partial inhibition of platelet aggregation produced complete inhibition in five patients at 650 mg and in one at 975 mg. At 1,300 mg, three patients still had only partial inhibition of platelet aggregation (aspirin resistance). Of the 33 inpatients with acute stroke, 24 had platelet aggregation studies done before further administration of aspirin. Of these, 19 had complete inhibition of platelet aggregation and three had partial inhibition, with production of complete inhibition of platelet aggregation at dose escalation; one patient was aspirin-resistant and the other noncompliant. Conclusions: How the inhibition of platelet aggregation relates to stroke prevention remains unclear. The ability of aspirin and the dose required to inhibit platelet aggregation may depend upon the individual.

AB - Background and Purpose: The purpose of this study was to assess the biological effect of aspirin as measured by the inhibition of platelet aggregation in patients taking aspirin for stroke prevention and in patients with acute stroke. Methods: We administered increasing doses of aspirin (325, 650, 975, and 1,300 mg daily) to 113 patients for stroke prevention and measured the inhibition of platelet aggregation in these patients and in 33 patients with acute stroke taking aspirin before stroke onset. Results: Eighty-five patients on ≤325 and six on ≥650 mg aspirin daily had complete inhibition of platelet aggregation. Increase of the dose by 325 mg in nine of the 22 patients with partial inhibition of platelet aggregation produced complete inhibition in five patients at 650 mg and in one at 975 mg. At 1,300 mg, three patients still had only partial inhibition of platelet aggregation (aspirin resistance). Of the 33 inpatients with acute stroke, 24 had platelet aggregation studies done before further administration of aspirin. Of these, 19 had complete inhibition of platelet aggregation and three had partial inhibition, with production of complete inhibition of platelet aggregation at dose escalation; one patient was aspirin-resistant and the other noncompliant. Conclusions: How the inhibition of platelet aggregation relates to stroke prevention remains unclear. The ability of aspirin and the dose required to inhibit platelet aggregation may depend upon the individual.

KW - Aspirin

KW - Cerebral infarction

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=0027447701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027447701&partnerID=8YFLogxK

U2 - 10.1161/01.STR.24.3.345

DO - 10.1161/01.STR.24.3.345

M3 - Article

C2 - 8446967

AN - SCOPUS:0027447701

VL - 24

SP - 345

EP - 350

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 3

ER -